Lupin Receives USFDA Inspection Report with Satisfactory Classification for Goa Facility

Lupin has received an Establishment Inspection Report (EIR) with a satisfactory Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (USFDA) for its Goa manufacturing facility. The EIR follows an inspection conducted from November 10 to 21, 2025, confirming compliance with regulatory standards. Lupin's managing director, Nilesh Gupta, highlighted this as a reflection of the company's focus on quality and regulatory adherence. Shares showed minor fluctuations following the announcement.